Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
Employees - 114000,
CEO - Mr. Robert B. Ford,
Sector - Healthcare,
Country - US,
Market Cap - 201.32B
Altman ZScore(max is 10): 5.23, Piotroski Score(max is 10): 8, Working Capital: $8900000000, Total Assets: $74356000000, Retained Earnings: $39056000000, EBIT: 7531000000, Total Liabilities: $34328000000, Revenue: $41217000000
AryaFin Target Price - $119.31 - Current Price $114.23 - Analyst Target Price $131.82
Ticker | ABT |
Index | S&P 500 |
Curent Price | 114.23 |
Change | 1.61% |
Market Cap | 201.32B |
Average Volume | 5.14M |
Income | 5.75B |
Sales | 41.22B |
Book Value/Share | 22.94 |
Cash/Share | 4.42 |
Dividend Est | 2.21 (1.94%) |
Dividend TTM | 2.20 (1.93%) |
Dividend Ex-Date | Jan 15, 2025 |
Employees | 114000 |
Moving Avg 20days | -1.02% |
Moving Avg 50days | -1.51% |
Moving Avg 200days | 3.22% |
Shares Outstanding | 1.73B |
Earnings Date | Oct 16 BMO |
Inst. Ownership | 76.62% |
Price/Earnings | 34.74 |
Forwad P/E | 22.13 |
PE Growth | 4.26 |
Price/Sales | 4.88 |
Price/Book | 4.98 |
Price/Cash | 25.85 |
Price/FCF | 31.04 |
Quick Ratio | 1.14 |
Current Ratio | 1.60 |
Debt/Equity | 0.38 |
Return on Assets | 7.85% |
Return on Equity | 14.87% |
Return on Investment | 10.92% |
Gross Margin | 50.98% |
Ops Margin | 16.38% |
Profit Margin | 13.94% |
RSI | 46.70 |
BETA(β) | 0.73 |
From 52week Low | 14.56% |
From 52week High | -6.09% |
EPS | 3.29 |
EPS next Year | 5.16 |
EPS next Qtr | 1.34 |
EPS this Year | 5.28% |
EPS next 5 Year | 8.15% |
EPS past 5 Year | 19.65% |
Sales past 5 Year | 6.10% |
EPS Y/Y | 11.65% |
Sales Y/Y | 3.15% |
EPS Q/Q | 14.65% |
Sales Q/Q | 4.85% |
Sales Surprise | 0.80% |
EPS Surprise | 0.65% |
ATR(14) | 1.91 |
Perf Week | 0.75% |
Perf Month | -1.47% |
Perf Quarter | -0.51% |
Perf Year | 6.36% |
Perf YTD | 3.78% |
Target Price | 131.82 |
AryaFin Engine© - An AI FinTech Venture - 2024 Disclaimer